Virtual Screening for Type II B Inhibitors of B-RafV600E Kinase

Curr Comput Aided Drug Des. 2020;16(3):222-230. doi: 10.2174/1573409915666190130162821.

Abstract

Background: B-RafV600E kinase was identified as an important target in current cancer treatment, and the type II B inhibitors show good qualities in preclinical studies. Therefore, it is very important to discover novel II B inhibitors of B-RafV600E kinase.

Methods: In order to discover novel II B inhibitors of B-RafV600E kinase, virtual screening against ZINC database was performed by using a combination of pharmacophore modelling, molecular docking, 3DQSAR model and binding free energy (ΔGbind) calculation studies. The inhibitory activities against A375 cell lines of the hit compounds were tested by using MTT assay.

Results: Five promising hit compounds were obtained after screening, and all the five hit compounds showed good inhibitory rates against A375 cell lines.

Conclusion: The combined approach of the virtual screening in our work is effective, which can be used to discover novel inhibitors with a new skeleton. In addition, the five compounds obtained from the screening showed good inhibitory rates against A375 cell lines, which can be considered to develop new II B inhibitors of B-RafV600E kinase.

Keywords: 3DQSAR; B-RafV600E kinase; binding free energy calculation; molecular docking; pharmacophore modelling; type II B inhibitors; virtual screening..

MeSH terms

  • Cell Line, Tumor
  • Drug Discovery*
  • Drug Screening Assays, Antitumor
  • Humans
  • Molecular Docking Simulation
  • Neoplasms / drug therapy
  • Neoplasms / metabolism
  • Protein Kinase Inhibitors / chemistry*
  • Protein Kinase Inhibitors / pharmacology*
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
  • Proto-Oncogene Proteins B-raf / metabolism
  • Quantitative Structure-Activity Relationship
  • Thermodynamics

Substances

  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins B-raf